Press Release
H.C. Wainwright Bioconnect Virtual Conference ,January 10 – 13, 2022
Erik Manting , Chief Executive Officer, will hold a company presentation and participate in virtual one-on-one investor meetings throughout the conference.
- Stern IR Virtual Client Event,
January 10 – 13, 2022
Erik Manting will participate in one-on-one investor meetings for the duration of the event.
- Allogeneic Cell Therapies Summit Europe, Digital Event,
January 18 – 20, 2022
Satwinder Kaur-Singh , Director of Research atImmunicum , will present “Understanding and Applying Allogeneic Dendritic Cell Biology” in a session dedicated to key considerations in designing cancer therapies to avoid later complications, onThursday January 20th , at12:30 p.m. CET .
- Redeye Theme: Fight Cancer Seminar – Outlook 2022,
January 20, 2022
Erik Manting will presentImmunicum and address Q&A in a session moderated by Redeye’s research analyst from 1:05 –1:25 p.m. CET . The Redeye Fight Cancer Seminar is an annually recurring event where Redeye invites some of the leading Nordic companies in this field to give updates on their priorities, challenges, and expected progress during 2022. The event is broadcast and accessible for all Redeye members via this link.
FOR MORE INFORMATION, PLEASE CONTACT:
Chief Executive Officer
E-mail: ir@immunicum.com
INVESTOR RELATIONS
Stern Investor Relations
Telephone: +1 212-698-8695
E-mail: brendan.payne@sternir.com
For
Kristina Windrup Olander
Telephone: +46 8 732 8400
E-mail: ir@immunicum.com
MEDIA RELATIONS
Telephone: +49 89 2388 7731
E-mail: immu@trophic.eu
About
www.immunicum.com
Attachment
- 20220103 - Immunicum_January_Events_FINAL_ENG
![](https://ml-eu.globenewswire.com/media/OWFhYjU3MWYtZDc1OC00ODFkLTg5YzMtMmM2YmJkZTM5MmM2LTEwMzc3MzY=/tiny/Immunicum-AB.png)
© OMX, source